Literature DB >> 12851527

A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.

D C Felmeden1, A D Blann, C G C Spencer, D G Beevers, G Y H Lip.   

Abstract

Loss of adequate endothelial cell function (associated with various cardiovascular syndromes such as hypertension) is most widely quantified by assessing flow-mediated dilatation (FMD) or measuring plasma markers such as von Willebrand factor (vWF). However, the relationship between these two methods is unclear, as is their relationship to 10-year cardiovascular risk (defined by the Framingham equation) and their response to intensive cardiovascular risk factor management. We tested the hypothesis that there is an inverse relationship between vWF and FMD by measuring both in 132 subjects, of whom 89 were hypertensive (mean blood pressure, 167/91 mmHg) and 43 were healthy normotensive (mean blood pressure, 133/80 mmHg). High-resolution ultrasound assessed endothelium-dependent brachial artery FMD following reactive hyperaemia after occlusion. Plasma vWF was defined by enzyme-linked immunosorbent assay. These measurements were repeated in the patients after 6 months of intensive cardiovascular risk factor management. vWF and FMD correlated significantly (r = -0.517, P < 0.001), and both correlated with 10-year cardiovascular risk using the Framingham equation (vWF, r = 0.48, P < 0.001; FMD, r = -0.624, P < 0.001). Following 6 months intensive cardiovascular risk factor management, plasma vWF was significantly reduced whereas FMD significantly increased (both P < 0.002). We conclude that two fundamentally different methods for assessing endothelial function correlate well with each other, as well as with 10-year cardiovascular risk. Six months of intensive risk factor management is beneficial to the endothelium, as defined by improved vWF and FMD. These methods might therefore be useful indices to identify patients at risk of future cardiovascular events, and may also assist in the understanding of early developments in the pathogenesis of vascular risk in hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12851527     DOI: 10.1097/00001721-200307000-00001

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  8 in total

1.  Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors.

Authors:  Leonel Daza; Martin Aguirre; Martin Jimenez; Rafael Herrera; J J Bollain
Journal:  Clin Rheumatol       Date:  2006-06-07       Impact factor: 2.980

Review 2.  The role of endothelial function and its assessment in rheumatoid arthritis.

Authors:  Faisel Khan; Bernat Galarraga; Jill J F Belch
Journal:  Nat Rev Rheumatol       Date:  2010-03-30       Impact factor: 20.543

Review 3.  MicroRNAs in hypertension: mechanisms and therapeutic targets.

Authors:  Sándor Bátkai; Thomas Thum
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

4.  Leptin links with plasminogen activator inhibitor-1 in human obesity: the SABPA study.

Authors:  Chiné Pieterse; Rudolph Schutte; Aletta E Schutte
Journal:  Hypertens Res       Date:  2015-03-05       Impact factor: 3.872

5.  Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity.

Authors:  Joshua S Davis; Tsin W Yeo; Kim A Piera; Tonia Woodberry; David S Celermajer; Dianne P Stephens; Nicholas M Anstey
Journal:  Crit Care       Date:  2010-05-18       Impact factor: 9.097

6.  Persimmon leaf flavonoid promotes brain ischemic tolerance.

Authors:  Mingsan Miao; Xuexia Zhang; Ming Bai; Linan Wang
Journal:  Neural Regen Res       Date:  2013-10-05       Impact factor: 5.135

7.  Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.

Authors:  Joshua A Beckman; Brian R Wood; Kevin L Ard; Christin N Price; Daniel A Solomon; Jonah P Zuflacht; Jessica Milian; Joshua C Prenner; Paul E Sax
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

8.  Effects of intermittent negative pressure treatment on circulating vascular biomarkers in patients with intermittent claudication.

Authors:  Henrik Hoel; Erik Mulder Pettersen; Lars Øivind Høiseth; Iacob Mathiesen; Arne Seternes; Ingebjørg Seljeflot; Jonny Hisdal
Journal:  Vasc Med       Date:  2021-05-13       Impact factor: 3.239

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.